Investigating the role of microRNAs in Alzheimer's disease progression
Official title: Synaptosomal MicroRNAs, Synaptic Damage and Cognitive Decline in Alzheimer's Disease
Funded at Texas Tech University Health Sciences Center at El Paso · NIH-10849918 · Data updated 2026-11-12
This study is looking at tiny molecules in the brain that might play a role in how Alzheimer's disease develops, by comparing brain samples from people with Alzheimer's and those without, to see how these molecules change and what that might mean for brain health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Sciences Center at El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | August 15, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $249,000 |
| NIH project number | 5R00AG065645-05 |
| Project ID | NIH-10849918 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease and healthy individuals for comparison.
✕Less likely to help
Patients with other forms of dementia or cognitive decline unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on understanding how specific microRNAs found in synapses contribute to the progression of Alzheimer's disease. By analyzing brain samples from individuals with Alzheimer's and healthy controls, the study aims to identify which microRNAs are altered in Alzheimer's patients. The researchers will use advanced techniques to sequence and characterize these microRNAs, exploring their potential roles in synaptic damage and cognitive decline. This could lead to new insights into the mechanisms of Alzheimer's and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for diagnosing or treating Alzheimer's disease.
How similar studies have gone: While the role of microRNAs in other conditions has been studied, this specific investigation into synaptosomal microRNAs in Alzheimer's disease is relatively novel.
Where this research is happening
-
Texas Tech University Health Sciences Center at El Paso
El Paso, United States Active
Researchers
- Principal investigator: Kumar, Subodh — Texas Tech University Health Sciences Center at El Paso
- Study coordinator: Kumar, Subodh
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Remote monitoring of Alzheimer’s changes in adults with Down syndrome
A study tests remote (at-home) ways to track Alzheimer’s-related thinking changes in adults with Down syndrome.
-
Tumor Susceptibility Gene 101: a microglial therapy approach to protect memory in Alzheimer’s disease
A Mayo Clinic team is studying a protein called TSG101 in brain immune cells to slow or prevent cognitive decline in Alzheimer’s disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.